Study Phase 2

A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis (X-PLORE)

Trial Information

Generic NameGuselkumabProduct NameTREMFYA®Therapeutic AreaSkin and Connective Tissue DiseasesEnrollment293% Female28.4%% White90.9%
Product ClassAntipsoriaticsSponsor Protocol NumberCNTO1959PSO2001Data PartnerJohnson & JohnsonCondition StudiedPsoriasisMean/Median Age (Years)44

Supporting Documentation

  • Collected Datasets Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.